Institut De Recherches Internationales Servier

This study compares two drug combinations for people with metastatic colorectal cancer who are not healthy enough for intensive chemotherapy. About 856 participants will receive either trifluridine/tipiracil plus bevacizumab or capecitabine plus bevacizumab. The goal is to see wh…

This study tests a new drug, vorasidenib, combined with standard chemotherapy (temozolomide) in people with a specific type of brain tumor (glioma) that has an IDH mutation. The goal is to find the safest dose and see if the combination helps control the tumor. About 51 participa…

This early-stage study tests whether combining two drugs—vorasidenib and pembrolizumab—can help people with a specific type of brain tumor (IDH-1 mutant glioma) that has come back or is growing. About 60 adults with grade 2 or 3 tumors will receive the treatment before and after …

This early-stage study is testing the safety of two experimental drugs, AG-120 and AG-221, when given together with standard chemotherapy for adults with newly diagnosed acute myeloid leukemia (AML) that has a specific genetic change (IDH1 or IDH2 mutation). The study involves ab…

This study tests whether adding the targeted drug ivosidenib (AG-120) to standard azacitidine helps adults with a specific genetic form of acute myeloid leukemia (IDH1-mutated AML) who are not healthy enough for strong chemotherapy. About 146 participants received either the drug…

This study was designed to test a new drug (S095033) combined with a standard chemotherapy (paclitaxel) in people with advanced or spreading esophageal cancer. The goal was to see if the combination was safe and could shrink tumors. However, the trial was withdrawn before enrolli…